DR1 and cancer: Specifically, patient subgroups NC2+, NC4+, and NC3− that achieve shorter survival are enriched for some clinical features of ‘aggressive cancers’, namely basal-like PAM50 phenotypes, ER negativity, and higher tumour grade.